作者
Shengzhi Liu,Yang Liu,Kazumasa Minami,Andy B. Chen,Qiaoqiao Wan,Yukun Yin,Liangying Gan,Aihua Xu,Nariaki Matsuura∥,Masahiko Koizumi,Yunlong Liu,Sungsoo Na,Jiliang Li,Harikrishna Nakshatri,Bai‐Yan Li,Hiroki Yokota
摘要
// Shengzhi Liu 1, 2 , Yang Liu 1, 2 , Kazumasa Minami 2, 3 , Andy Chen 2 , Qiaoqiao Wan 2 , Yukun Yin 4 , Liangying Gan 4 , Aihua Xu 4 , Nariaki Matsuura 5 , Masahiko Koizumi 3 , Yunlong Liu 6 , Sungsoo Na 2 , Jiliang Li 4 , Harikrishna Nakshatri 7 , Bai-Yan Li 1 and Hiroki Yokota 2 1 Department of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin 150081, China 2 Department of Biomedical Engineering, Indiana University at Purdue University, Indianapolis, IN 46202, USA 3 Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine Suita, Osaka 565-0871, Japan 4 Department of Biology, Indiana University at Purdue University, Indianapolis, IN 46202, USA 5 Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-8511, Japan 6 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA 7 Department of Surgery, Simon Cancer Research Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA Correspondence to: Hiroki Yokota, email: hyokota@iupui.edu Bai-Yan Li, email: liby@ems.hrbmu.edu.cn Keywords: breast cancer; bone resorption; checkpoint kinase; eIF2α Received: October 27, 2017 Accepted: January 13, 2018 Published: January 19, 2018 ABSTRACT DNA damage response plays a critical role in tumor growth, but little is known about its potential role in bone metabolism. We employed selective inhibitors of Chk1 and examined their effects on the proliferation and migration of mammary tumor cells as well as the development of osteoblasts and osteoclasts. Further, using a mouse model of bone metastasis we evaluated the effects of Chk1 inhibitors on bone quality. Chk1 inhibitors blocked the proliferation, survival, and migration of tumor cells in vitro and suppressed the development of bone-resorbing osteoclasts by downregulating NFATc1. In the mouse model, Chk1 inhibitor reduced osteolytic lesions and prevented mechanical weakening of the femur and tibia. Analysis of RNA-seq expression data indicated that the observed effects were mediated through the regulation of eukaryotic translation initiation factor 2 alpha, stress to the endoplasmic reticulum, S100 proteins, and bone remodeling-linked genes. Our findings suggest that targeting Chk1 signaling without adding DNA damaging agents may protect bone from degradation while suppressing tumor growth and migration.